The market has been down on Geron Corporation (GERN) stock recently. GERN gets a Bearish score from InvestorsObserver's Stock Sentiment Indicator.
What is Stock Sentiment?
Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.
As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.
Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive.
InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend.
Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .
What's Happening With GERN Stock Today?
Geron Corporation (GERN) stock is higher by 6.79% while the S&P 500 is lower by -1.23% as of 12:50 PM on Tuesday, May 11. GERN has gained $0.08 from the previous closing price of $1.25 on volume of 1,405,331 shares. Over the past year the S&P 500 is up 41.18% while GERN is lower by -8.90%. GERN lost -$0.28 per share in the over the last 12 months.
To see the top 5 stocks in the Biotechnology industry click here.
More About Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses global rights to this drug.
Click Here to get the full Stock Score Report on Geron Corporation (GERN) Stock.
